|
**Overview**: Histopathology Large Biopsy Panel**Introduction**: The Histopathology Large Biopsy Panel is a diagnostic tool designed to analyze large biopsy specimens using FFPE tissue. In India, large biopsies (excisional/incisional) are crucial for accurate diagnosis in tumors (breast, soft tissue, GI), with detailed morphology essential for grading, staging, and margin assessment. High morbidity from under-processing in rural/low-SES patients with large masses, limited histopathology expertise, delayed or inaccurate diagnosis leading to inappropriate surgery or delayed chemo. Per histopathology practices aligned with ICMR and Indian Academy of Pathology guidelines, the test employs microscopy for tissue morphology, cellular details, and pathologist review over 1-2 days (depending on size/complexity), valuable for comprehensive evaluation of large specimens. This diagnostic falls under tissue analysis and targets patients with palpable masses or suspected malignancy requiring excision, addressing accurate detection to guide definitive therapy. With elevated morbidity due to diagnostic delays, the test supports public health efforts by enabling precise histopathological assessment and reducing cancer misdiagnosis. Its FFPE-based approach ensures reliable morphological analysis.**Other Names**: Histo Large Pnl.**FDA Status**: FDA approved, CLIA certified for histopathology, compliant with 2025 standards.**Historical Milestone**: Large biopsy histopathology standard; in India, used in oncology/surgery centers.**Purpose**: The test assesses 3 parameters including tissue morphology to guide large biopsy analysis, evaluate pathology, inform treatment.**Test Parameters**: 1. Tissue Morphology, 2. Cellular Details, 3. Pathologist Review.**Pretest Condition**: No fasting required; patients should have large biopsy specimen.**Specimen**: Formalin-fixed paraffin-embedded block (0.5â€"2 cm³), transported within specified times to maintain sample integrity.Sample Stability: Indefinite when properly stored in formalin/paraffin; review possible long-term.**Medical History**: Patients should provide details on clinical suspicion, imaging, surgical notes.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of inaccurate diagnosis including wrong treatment, benefits of detailed analysis, and no additional discomfort (uses existing block).**Procedural Considerations**: The test involves slide preparation and microscopy by trained pathologists to ensure accurate review, avoid sampling bias, and provide detailed report within 1-2 days (or longer for complex cases) using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Poor fixation, inadequate sampling, or interpretation differences can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Detailed findings guide staging/therapy, necessitating specialist input.**Specialist Consultation**: Oncologists or surgeons should be consulted for management.**Additional Supporting Tests**: IHC, frozen section correlation for confirmation.**Test Limitations**: Dependent on block quality; comprehensive approach required.**References**: Indian Journal of Pathology 2024, Oncology Studies India 2023. |
